Loading...
•
Dec 31, 2020
Avadel Q4 2020 Earnings Report
Announced financial results for the fourth quarter and year ended December 31, 2020.
Key Takeaways
Avadel Pharmaceuticals reported no revenue for Q4 2020 due to the sale of sterile injectable products. R&D expenses decreased, while SG&A expenses increased. The company reported a net loss of $11.3 million, or ($0.19) per diluted share. Cash, cash equivalents, and marketable securities totaled $221.4 million as of December 31, 2020.
No revenue was reported for Q4 2020 due to the sale of sterile injectable products.
R&D expenses decreased to $5.3 million compared to $7.8 million in Q4 2019.
SG&A expenses increased to $9.0 million compared to $7.7 million in Q4 2019.
Net loss for Q4 2020 was $11.3 million, or ($0.19) per diluted share.